Boundless Bio's reverse merger; CARsgen wins first solid tumor approval for CAR-T
Endpoints News reported Boundless Bio's reverse merger and CARsgen's world-first approval of a CAR-T therapy for solid tumors in China.
Profile of Boundless Bio created from news harvest. To be enriched by user.
Endpoints News reported Boundless Bio's reverse merger and CARsgen's world-first approval of a CAR-T therapy for solid tumors in China.
Chief Executive Officer